<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03910647</url>
  </required_header>
  <id_info>
    <org_study_id>PPIs with kidney function</org_study_id>
    <nct_id>NCT03910647</nct_id>
  </id_info>
  <brief_title>Effect of Daily Use Proton Pump Inhibitors for One Month on Kidney Function</brief_title>
  <official_title>the Effect of Daily Use of Proton Pump Inhibitors for One Month on Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study to: evaluate the association between prolonged use of PPI and adverse
      renal outcomes on patients with normal renal function and others with abnormal renal function
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Proton pump inhibitors (PPIs) are one of the most widely used classes of drugs and are
      prescribed primarily for gastric acid-related diseases, eradication of Helicobacter pylori,
      and prevention of nonsteroidal anti-inflammatory drug (NSAID)-induced gastropathy,and
      gastroesophagial reflux diseases . Although PPIs have an excellent overall safety profile,
      some severe adverse effects, which include bone fracture, dementia, myocardial infarction,
      infections, micronutrient deficiencies, and kidney diseases,PPIs may trigger acute
      interstitial nephritis,a potentially sever adverse event commonly associated with acute
      kidney injury The increase in prescription and inadequate use of this class of medication
      calls for studies on the effects of prolonged PPI therapy on renal function.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2019</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>kidney function</measure>
    <time_frame>one month</time_frame>
    <description>eGFR=175xage(y/0)x^(-0.203)xplasma creatinine (mg/dl)x^(-1.154)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Proton Pump Inhibitor Allergy</condition>
  <arm_group>
    <arm_group_label>pantoprazole with normal kidney function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>use pantoprazole for one month and after one month i will do for them kidney functions test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pantoprazole with abnormal kidney function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>use pantoprazole for one month and after one month i will do for them kidney functions test</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pantoprazole</intervention_name>
    <description>effect of this drug on renal function</description>
    <arm_group_label>pantoprazole with abnormal kidney function</arm_group_label>
    <arm_group_label>pantoprazole with normal kidney function</arm_group_label>
    <other_name>Protonix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with peptic ulcer disease or gastroesophagial reflux with normal l renal
             function

          -  patients with peptic ulcer disease or gastroeosophagial reflux with abnormal renal
             function

        Exclusion Criteria:

          -  1- cigarette smoker: Cigarette smoking status was defined categorically as
             current,former, or never smoker at baseline.

             2-biabetic patients: diabetes mellitus is defined by a fasting blood glucose
             concentration &gt;_ 126 mg/dl ,random glucose level of &gt;200 mg/dl.

             3-patients take corticosteroid 4-patients with hypersensitivity to these drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>samir k abdel-hameed</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>mohammad y kobeisy, prof</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>hanan m israil</last_name>
    <phone>01007417192</phone>
    <email>dr.hananmonsif@yahoo.com</email>
  </overall_contact>
  <reference>
    <citation>Desbuissons G, Deray G, Mercadal L. [Proton pump inhibitors and kidney]. Nephrol Ther. 2018 Apr;14 Suppl 1:S115-S124. doi: 10.1016/j.nephro.2017.06.005. Epub 2017 Dec 20. French.</citation>
    <PMID>29274872</PMID>
  </reference>
  <reference>
    <citation>Mak SK, Loo CK, Wong PN, Lo KY, Tong GM, Lam EK, Wong AK. A retrospective study on efficacy of proton-pump inhibitor-based triple therapy for eradication of Helicobacter pylori in patients with chronic renal failure. Singapore Med J. 2003 Feb;44(2):74-8.</citation>
    <PMID>14503780</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>April 3, 2019</study_first_submitted>
  <study_first_submitted_qc>April 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2019</study_first_posted>
  <last_update_submitted>July 15, 2019</last_update_submitted>
  <last_update_submitted_qc>July 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>hanan monsif israil markous</investigator_full_name>
    <investigator_title>director .samir kamal abdel-hameed</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

